Cargando…

Phyllodes tumors of the breast: Adjuvant radiation therapy revisited

BACKGROUND: Phyllodes tumors (PT) are rare entity and surgical resection is the cornerstone of treatment. No standard of care exists regarding adjuvant treatment especially radiation therapy (RT). PATIENTS AND METHODS: We analyzed all patients with non-metastatic, resected phyllodes tumors who prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutrus, Rimoun R., Khair, Sandy, Abdelazim, Yasser, Nasr, Sarah, Ibraheem, Maher H., Farahat, Ahmed, El Sebaie, Medhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079270/
https://www.ncbi.nlm.nih.gov/pubmed/33865208
http://dx.doi.org/10.1016/j.breast.2021.03.013
_version_ 1783685191548534784
author Boutrus, Rimoun R.
Khair, Sandy
Abdelazim, Yasser
Nasr, Sarah
Ibraheem, Maher H.
Farahat, Ahmed
El Sebaie, Medhat
author_facet Boutrus, Rimoun R.
Khair, Sandy
Abdelazim, Yasser
Nasr, Sarah
Ibraheem, Maher H.
Farahat, Ahmed
El Sebaie, Medhat
author_sort Boutrus, Rimoun R.
collection PubMed
description BACKGROUND: Phyllodes tumors (PT) are rare entity and surgical resection is the cornerstone of treatment. No standard of care exists regarding adjuvant treatment especially radiation therapy (RT). PATIENTS AND METHODS: We analyzed all patients with non-metastatic, resected phyllodes tumors who presented to our institution from January 2005 through December 2019. Primary study endpoints included local recurrence free survival (LRFS) and overall survival (OS). RESULTS: One hundred and eight patients were analyzed (patients with incomplete treatment and follow up data were excluded). Fifty patients had benign phyllodes, 26 patients had borderline and 32 patients had malignant phyllodes. In the benign group, no significant difference in LRFS was observed between patients who received adjuvant RT (n = 3) and those who did not (5-year LRFS 100% vs. 85% respectively, p = 0.49). The 5 year OS for patients who received RT was 60% vs. 89% for those who did not (p 0.40). In the borderline/malignant group, adjuvant RT significantly improved five year LRFS (90% in the RT group vs. 42% in the no RT group, p = 0.005). The 5 year LRFS in patients treated with margin negative breast conserving surgery and RT was 100% vs. 34.3% in patients who did not receive RT (p 0.022). Patients treated with mastectomy and RT had a 5 year LRFS of 100% vs. 83% for patients who did not receive RT (p 0.24). On multivariate analysis, radiation therapy was independently associated with decreased hazard of local failure (HR 0.21, CI 0.05–0.89, p = 0.03). No difference in OS was found between the RT and no RT groups (5-year OS was 52% vs. 45% respectively, p 0.54). CONCLUSION: The results of the current study confirm the excellent prognosis of benign phyllodes tumors; warranting no further adjuvant treatment after margin-negative surgical resection. For patients with borderline/malignant phyllodes tumors, adjuvant radiation therapy significantly improved LRFS after margin negative wide local excision; however, patients treated with mastectomy did not attain the same benefit from adjuvant irradiation.
format Online
Article
Text
id pubmed-8079270
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80792702021-04-29 Phyllodes tumors of the breast: Adjuvant radiation therapy revisited Boutrus, Rimoun R. Khair, Sandy Abdelazim, Yasser Nasr, Sarah Ibraheem, Maher H. Farahat, Ahmed El Sebaie, Medhat Breast Original Article BACKGROUND: Phyllodes tumors (PT) are rare entity and surgical resection is the cornerstone of treatment. No standard of care exists regarding adjuvant treatment especially radiation therapy (RT). PATIENTS AND METHODS: We analyzed all patients with non-metastatic, resected phyllodes tumors who presented to our institution from January 2005 through December 2019. Primary study endpoints included local recurrence free survival (LRFS) and overall survival (OS). RESULTS: One hundred and eight patients were analyzed (patients with incomplete treatment and follow up data were excluded). Fifty patients had benign phyllodes, 26 patients had borderline and 32 patients had malignant phyllodes. In the benign group, no significant difference in LRFS was observed between patients who received adjuvant RT (n = 3) and those who did not (5-year LRFS 100% vs. 85% respectively, p = 0.49). The 5 year OS for patients who received RT was 60% vs. 89% for those who did not (p 0.40). In the borderline/malignant group, adjuvant RT significantly improved five year LRFS (90% in the RT group vs. 42% in the no RT group, p = 0.005). The 5 year LRFS in patients treated with margin negative breast conserving surgery and RT was 100% vs. 34.3% in patients who did not receive RT (p 0.022). Patients treated with mastectomy and RT had a 5 year LRFS of 100% vs. 83% for patients who did not receive RT (p 0.24). On multivariate analysis, radiation therapy was independently associated with decreased hazard of local failure (HR 0.21, CI 0.05–0.89, p = 0.03). No difference in OS was found between the RT and no RT groups (5-year OS was 52% vs. 45% respectively, p 0.54). CONCLUSION: The results of the current study confirm the excellent prognosis of benign phyllodes tumors; warranting no further adjuvant treatment after margin-negative surgical resection. For patients with borderline/malignant phyllodes tumors, adjuvant radiation therapy significantly improved LRFS after margin negative wide local excision; however, patients treated with mastectomy did not attain the same benefit from adjuvant irradiation. Elsevier 2021-04-07 /pmc/articles/PMC8079270/ /pubmed/33865208 http://dx.doi.org/10.1016/j.breast.2021.03.013 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Boutrus, Rimoun R.
Khair, Sandy
Abdelazim, Yasser
Nasr, Sarah
Ibraheem, Maher H.
Farahat, Ahmed
El Sebaie, Medhat
Phyllodes tumors of the breast: Adjuvant radiation therapy revisited
title Phyllodes tumors of the breast: Adjuvant radiation therapy revisited
title_full Phyllodes tumors of the breast: Adjuvant radiation therapy revisited
title_fullStr Phyllodes tumors of the breast: Adjuvant radiation therapy revisited
title_full_unstemmed Phyllodes tumors of the breast: Adjuvant radiation therapy revisited
title_short Phyllodes tumors of the breast: Adjuvant radiation therapy revisited
title_sort phyllodes tumors of the breast: adjuvant radiation therapy revisited
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079270/
https://www.ncbi.nlm.nih.gov/pubmed/33865208
http://dx.doi.org/10.1016/j.breast.2021.03.013
work_keys_str_mv AT boutrusrimounr phyllodestumorsofthebreastadjuvantradiationtherapyrevisited
AT khairsandy phyllodestumorsofthebreastadjuvantradiationtherapyrevisited
AT abdelazimyasser phyllodestumorsofthebreastadjuvantradiationtherapyrevisited
AT nasrsarah phyllodestumorsofthebreastadjuvantradiationtherapyrevisited
AT ibraheemmaherh phyllodestumorsofthebreastadjuvantradiationtherapyrevisited
AT farahatahmed phyllodestumorsofthebreastadjuvantradiationtherapyrevisited
AT elsebaiemedhat phyllodestumorsofthebreastadjuvantradiationtherapyrevisited